3.17a_05 Oral Hypoglycaemics
Oral hypoglycaemics
Session overview
Description
This session provides an overview of oral hypoglycaemic agents, their indications, cautions and the clinical guidelines governing their use.
Learning objectives
By the end of this session you will be able to:
- describe the differences between the types of oral hypoglycaemics available and their mechanisms of action
- explain the indications of the various oral hypoglycaemics (OHGs) and cautions around their use
- discuss the NICE guidance and be able to compare it to the American Diabetes Association and the European Association for the Study of Diabetes guidelines
- advise on medication use during intercurrent illness
Type 2 diabetes is a long-term metabolic condition characterised by insulin resistance, resulting in hyperglycaemia and associated with a reduction in pancreatic insulin production over time. Treatment is aimed at effectively controlling blood glucose and maintenance of glycated haemoglobin(read a full definition of this term) (HbA1c) at or below the target value set for each individual patient(read a full definition of this term), to minimise the risk of long-term microvascular and macrovascular complications [1](read details regarding the reference).
Lifestyle interventions such as weight loss, smoking cessation and regular exercise can help to reduce hyperglycaemia and reduce cardiovascular risk and encouraged at every opportunity. Hypoglycaemic medications should be prescribed to augment lifestyle interventions, when these changes are not adequate to control blood-glucose alone.
This session provides an overview of oral hypoglycaemic agents, their indications, cautions and the clinical guidelines governing their use. It can be found in people with obesity and sedentary lifestyles and can be complicated by hypertension, dyslipidaemia and increases cardiovascular risk.
- 3.17b_06 Calcium and Bone Metabolism Disorders in ...
- Posted By eIntegrity Healthcare e-Learning
- Posted Date: 2024-09-30
- Location:Online
- This session looks at the common presentations of calcium and bone metabolic disorders and outlines a rational approach to their investigation. This session was reviewed by Khyati Bakhai and last updated in February 2020.
- 3.17b_05 Assessing a Patient with an Electrolyte I...
- Posted By eIntegrity Healthcare e-Learning
- Posted Date: 2024-09-30
- Location:Online
- This session explores the common and important causes of electrolyte imbalances commonly seen in primary care, particularly sodium and potassium, and presents a set of typical case studies of patients who have electrolyte disturbances. This session was re
- 3.17b_04 Managing a Patient with Hyperthyroidism i...
- Posted By eIntegrity Healthcare e-Learning
- Posted Date: 2024-09-30
- Location:Online
- This session describes the causes, initial investigation and treatment options for patients who present to a general practitioner with hyperthyroidism.This session was reviewed by Khyati Bakhai and last updated in February 2020.
- 3.17b_03 Prescribing Thyroxine in Primary Care
- Posted By eIntegrity Healthcare e-Learning
- Posted Date: 2024-09-30
- Location:Online
- This session will discuss the initiation of thyroxine for the management of primary and secondary thyroid failure, together with appropriate recommendations for monitoring stable patients.This session was reviewed by Khyati Bakhai and last updated in July
- 3.17b_02 Subclinical Hypothyroidism Diagnosis and ...
- Posted By eIntegrity Healthcare e-Learning
- Posted Date: 2024-09-30
- Location:Online
- This session covers the presentation, diagnosis, investigation and initial management of hypothyroidism in primary care. This session was reviewed by Khyati Bakhai and last updated in June 2021.